Why, Who, What, Where, When and How to use biosimilar insulins

NHS spending nearly DOUBLES to almost a billion in a decade – nearly one third is spent on Insulins. Biosimilars are comparatively less costly options – do they offer similar efficacy and safety? What are the cost implications? This session will uncover myths and facts about biosimilar insulins.

Learning outcomes:

  • Understand what biosimilar insulins are.
  • Outline the evidence that supports where the biosimilars can be used
  • Define who will benefit from use of biosimilars and when this is best considered.
  • Consider how the availability of biosimilar insulin will impact clinical practice and you

*This session is organised and remunerated by Mylan

Wednesday 30 October 2019

12:40 - 13:20

Commissioning & Integrated Care


Specialist pharmacist, North Bristol NHS Trust
Senior Clinical Pharmacist Diabetes and Endocrinology, County Durham and Darlington NHS Foundation Trust